Dinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates.
Chemistry
; 30(32): e202400217, 2024 Jun 06.
Article
em En
| MEDLINE
| ID: mdl-38574234
ABSTRACT
Cancer is one of the deadliest diseases worldwide. Chemotherapy remains one of the most dominant forms for anticancer treatment. Despite their clinical success, the used chemotherapeutic agents are associated with severe side effect and pharmacological limitations. To overcome these drawbacks there is a need for the development of new types of chemotherapeutic agents. Herein, the chemical synthesis and biological evaluation of dinuclear rhenium(I) complexes as potential chemotherapeutic drug candidates are proposed. The metal complexes were found to be internalized by an energy dependent endocytosis pathway, primary accumulating in the mitochondria. The rhenium(I) complexes demonstrated to induce cell death against a variety of cancer cells in the micromolar range through apoptosis. The lead compound showed to eradicate a pancreatic carcinoma multicellular tumor spheroid at micromolar concentrations.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Rênio
/
Apoptose
/
Complexos de Coordenação
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Chemistry
Ano de publicação:
2024
Tipo de documento:
Article